Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于贝达药业股份有限公司2018年（第一期）股票期权激励计划首次授予部分第三次行权等相关事项的法律意见书
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 stock option incentive plan of Betta Pharmaceuticals Co., Ltd. It details the legal review and confirmation of the stock option plan's approval, authorization, price adjustments, cancellations, and the third exercise of stock options. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to corporate governance and stock option incentive matters. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. The content fits best under a category related to governance or management information about stock option plans and related approvals. Given the options, the closest and most appropriate classification is "Board/Management Information (MANG)", as it involves board approvals and management decisions on stock option plans.
2021-04-28 Chinese
关于贝达药业股份有限公司2018年（第二期）股票期权激励计划首次授予部分第二次行权及预留部分第一次行权等相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 (second phase) stock option incentive plan of Betta Pharmaceuticals Co., Ltd. It details the legal procedures, approvals, authorizations, adjustments to stock option exercise prices, cancellations of stock options, and the exercise of stock options under the plan. The document is not a financial report, earnings release, or regulatory announcement but a specialized legal opinion on stock option incentive plan matters. It does not fit categories like Annual Report, Earnings Release, or Capital/Financing Update. It is a standalone legal opinion related to stock option incentive plans, which is best classified under Regulatory Filings (RNS) as it does not match other more specific categories and is a legal compliance document.
2021-04-28 Chinese
关于注销公司2018年股票期权激励计划部分已授期权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the cancellation of part of its 2018 stock option incentive plans, including adjustments to the list of incentive recipients and option quantities. It includes references to board and supervisory meetings, independent director opinions, legal opinions, and detailed descriptions of stock option grants, cancellations, and adjustments. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not a regulatory certification or a voting result announcement. The content focuses on management decisions regarding stock option plans and their adjustments, which is typical of a Capital/Financing Update. The document length (7315 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-28 Chinese
2018年（第二期）股票期权激励计划首次授予期权第二个行权期可行权激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of stock option incentive plan participants for Betta Pharmaceuticals Co., Ltd. It details the names and categories of directors, senior management, and core technical personnel eligible for exercising stock options under the 2018 stock option incentive plan. The content focuses on personnel and stock option allocations rather than financial results, regulatory certifications, or voting results. It is not an annual report, earnings release, or management discussion. It is also not a voting result announcement or a capital/financing update per se, but rather a disclosure related to stock option incentives for management and key personnel. This type of document aligns best with Remuneration Information filings, which cover compensation and incentive plans for executives and directors. The document length is under 5,000 characters, but it contains substantive data about stock option allocations rather than just an announcement of a report publication or certification. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2021-04-28 Chinese
关于2018年（第一期）股票期权激励计划首次授予股票期权第三个行权期可行权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the third exercise period of the company's 2018 stock option incentive plan. It includes descriptions of the stock option plan, adjustments to exercise prices, cancellations of unexercised options, lists of eligible participants, and legal and board approvals. The content focuses on stock option exercises and related corporate governance matters rather than financial results or earnings. It is not a full annual or interim report, nor an earnings release or investor presentation. It is also not a regulatory filing or report publication announcement since it contains substantive details about the stock option exercise event. The document is best classified as a Capital/Financing Update (CAP) because it relates to changes in the company's capital structure through stock option exercises and related adjustments.
2021-04-28 Chinese
2018年（第二期）股票期权激励计划预留期权第一个行权期可行权激励对象名单
Director's Dealing Classification · 95% confidence The document is titled as a list of stock option incentive plan reserved options and the first exercise period exercisable incentive object list for the year 2018. It lists names and categories of directors, senior management, and core technical personnel eligible for stock options. This is a detailed disclosure of stock option allocations to management and key personnel, which is related to insider share transactions or dealings by directors and executives. The document length is short (1714 characters) and it is not a report or announcement of a report but a direct disclosure of share-related transactions by insiders. Therefore, it fits best under the category of Director's Dealing (DIRS).
2021-04-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.